Abstract: Objective This study aimed to reveal the effectiveness and safety of tenofovir amibufenamide (TMF) in the real world,compared with tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB). Methods In this study, TMF or TAF treated-chronic hepatitis B patients were included at the Affiliated Hospital of Southwest Medical University and the First People′s Hospital of Neijiang City from August 2022 to July 2023. 64 patients were included in the TMF group, 57 patients were included in the TAF group. All patients received 24 weeks of treatment.The virological response (HBV DNA < 100 IU/mL) rate, alanine aminotransferase recovery (ALT＜40 U/L) rate,changes of hepatitis B surface antigen (HBsAg), renal function, and blood lipid profile were compared between baseline and after 24 weeks of treatment (intergroup and intragroup). Results At baseline, the age, ALT, HBVDNA, and HBsAg levels of the patients in the TMF group and the TAF group were not statistical significance between two groups (P>0. 05). After 24 weeks of treatment, △HBsAg, virological response (VR) rate in TMF group and TAF group were (TMF -477.98 IU/mL vs. TAF -133.63 IU/mL, P=0.117)、(95.31% vs. 84.21%, P=0.041),respectively. After 24 weeks of treatment, ALT recovery rate, △Cr, △eGFR, △TG, and △TC were not statistical significance between two groups (P>0. 05). For treatment-naive patients, VR rates at week 24 were 97.05% in the TMF group and 76% in the TAF group (P=0.013). Conclusion TMF had profound antiviral effectiveness and no adverse effects on renal function or blood lipids. Additionally, TMF was more efficient than TAF in inhibiting viral replication for treatment-naive patients.

Key words: Chronic hepatitis B, Tenofovir amibufenamide, Tenofovir alafenamide